Close
Novotech
Jabsco PureFlo 21 Single Use

Drug Research

Rising Demand Drive Small Molecule Innovator CDMO Market

According to insights, the market for contract development and manufacturing organizations (CDMOs) specializing in small molecule innovation is estimated to reach a value of $48.09 billion in 2023 and $89.43 billion in 2033. The sales in this market are...

Cellefill, a new integrated solution to fast-track cell, gene and biological therapies

Aseptic fill/finish experts Flexicon Liquid Filling, part of Watson-Marlow Fluid Technology Solutions (WMFTS), and barrier technology specialists Franz Ziel GmbH, announces Cellefill™, a turnkey, vial fill/finish system with an integrated barrier solution. Enhancing good manufacturing practice (GMP), customer compliance and...

Rapid Expansion Projected In Pharma Sterility Testing Market

Recent insights suggest that the pharmaceutical sterility testing market is projected to grow from $0.636 billion in 2023 to $1.0223 billion by 2032. Factors such as the increasing emphasis on quality and sterility, government investments, and the introduction of...

Gene-Edited Neutrophils Show Potential Against Lung Cancer

In Hong Kong, lung cancer continues to be the most prevalent form of cancer. Despite its status as a prominent global cause of cancer-related deaths, there is still a need for a significant breakthrough in its treatment. The Faculty...

Telix Opens $21.2M European Radiopharmaceutical Production Facility

Telix Pharmaceuticals Limited opened Telix Manufacturing Solutions, the company's radiopharmaceutical production facility located in Belgium. The 2,800 square meter facility is one of Europe's largest radiopharmaceutical production facilities, according to the company. It will serve as Telix’s primary manufacturing site...

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

Charles River Laboratories International, Inc. and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related neurodegeneration (PLAN), today announced a plasmid DNA manufacturing...

Quell Therapeutics, AstraZeneca Partner on Engineered Treg Cell Therapies

Quell Therapeutics Ltd, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »